• Hot Tips Archive
Mad Hedge Fund Trader
  • About
  • Store
  • Luncheons
  • Testimonials
  • Free Newsletter / Hot Tips
  • Contact Ussupport@madhedgefundtrader.com
  • Login
  • Search
  • Menu

Buy Before the Rally

Biotech Letter

Over the past month, COVID-19 vaccine developers like Pfizer (PFE), Moderna (MRNA), and AstraZeneca (AZN) have offered the world a bit of good news.

For the first time since the pandemic started, we have seen a light at the end of this crisis’ tunnel.

This time around next year, the economy should be close to its normal state.

Before we see the struggling financial market completely recover, you might want to consider buying shares of an under-the-radar COVID-19 vaccine developer that could be on its way to performing better in 2021: Merck (MRK).

Major healthcare and drug stocks rarely get this cheap relative to the S&P 500 in the last 15 years, Merck is a prime example of this once-in-a-blue-moon phenomenon.

Although it was slow to start and report on updates in its COVID-19 vaccine, Merck has been making strides in emerging as a major competitor against Gilead Sciences (GILD) when it comes to developing a COVID-19 drug.

To date, Merck landed a $356 million supply agreement with the US government to deliver 60,000 to 100,000 doses of its oral antiviral drug for COVID-19.

While vaccines are definitely valuable in helping prevent the spread of the virus, there is another important market that healthcare companies are targeting: the hospitalized COVID-19 patients.

With this recent announcement from Merck, it’s obvious that the company has its hands on both the vaccine market and the hospitalized patient group.

In terms of vaccine development, Merck may be behind Pfizer and Moderna but this New Jersey-based titan has one of the leading vaccine franchises in the industry.

The frontrunner in Merck’s vaccine franchise is its cervical cancer vaccine Gardasil, which is estimated to be worth half of its current market value of approximately $200 billion.

The company is also anticipated to record high single-digit earnings growth in the years to come, thanks to the 2021 spinoff of its Organon unit.

Following Pfizer and Mylan footsteps in the newly formed Viatris (VTRS), Organon will be used to unload the slower-growth products from Merck’s current portfolio.

With the purging of its product portfolio of the low-performing treatments comes the expansion of Merck’s R&D courtesy of its $2.75 acquisition of biotechnology startup VelosBio. 

Thanks to this deal, Merck will gain access to VelosBio’s prized VLS-101, which is basically a miniature chemotherapy grenade that would disintegrate cancer cells.

This collaboration could turn out into another moneymaker for the company.

Merck is no stranger when it comes to picking winning oncology investments.

The last massive deal it completed was a $1.16 billion deal with AstraZeneca in 2017, with the two companies agreeing to milestone payments of up to $6.15 billion.

This partnership brought to life one of the highest-selling cancer drugs in the world today, Lynparza.

To date, Lynparza is not only used for prostate cancer but also gained expanded approval for breast and pancreatic cancer.

In the third quarter of 2020 alone, even with the pandemic still wreaking havoc everywhere, Merck’s share of profits for Lynparza jumped 59% year over year to reach $196 million—a number that is projected to continue to climb as the drug awaits more approvals from the EU.

Merck offers the most attractive upside case among the healthcare stocks today, with the company projected to report consistent revenue growth until at least 2025.

Moreover, this pharmaceutical company has a strong balance sheet, as seen in its recent acquisitions and potential partnerships still underway.

So far, Merck’s shares are down 12% this year to only $80, with the stock trading 13 times its projected earnings in 2021 at $6.29 per share.

This pharmaceutical giant has a stable dividend yield of 3.3%, which is double the S&P 500.

As the economy continues with its recovery, you can expect Merck to get stronger and the stock should rally sooner rather than later.

Hence, buying it before it completely bounces back could allow you to cash in some spectacular returns.

December 29, 2020/by Mad Hedge Fund Trader
Tags: (CRSP), (GLPG), (PTI), (VRTX)
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-12-29 11:00:432021-01-02 20:01:13Buy Before the Rally
You might also like
March 27, 2019
The 2020 Dark Horses of Biotech and COVID-19
January 19, 2021
Monopoly is the Name of the Game

Archives

  • 2021 (298)
    • February (140)
    • January (158)
  • 2020 (2078)
    • December (170)
    • November (184)
    • October (169)
    • September (177)
    • August (171)
    • July (169)
    • June (186)
    • May (192)
    • April (201)
    • March (183)
    • February (144)
    • January (131)
  • 2019 (1772)
    • December (132)
    • November (128)
    • October (168)
    • September (128)
    • August (173)
    • July (138)
    • June (113)
    • May (159)
    • April (169)
    • March (169)
    • February (141)
    • January (153)
  • 2018 (1799)
    • December (150)
    • November (158)
    • October (194)
    • September (131)
    • August (150)
    • July (133)
    • June (128)
    • May (162)
    • April (185)
    • March (155)
    • February (153)
    • January (100)
  • 2017 (520)
    • December (96)
    • November (114)
    • October (52)
    • September (47)
    • August (63)
    • July (38)
    • June (52)
    • May (58)
  • 2016 (1369)
    • December (116)
    • November (107)
    • October (133)
    • September (110)
    • August (125)
    • July (98)
    • June (111)
    • May (142)
    • April (119)
    • March (112)
    • February (91)
    • January (105)
  • 2015 (1290)
    • December (98)
    • November (94)
    • October (89)
    • September (106)
    • August (105)
    • July (87)
    • June (72)
    • May (101)
    • April (134)
    • March (145)
    • February (122)
    • January (137)
  • 2014 (1490)
    • December (112)
    • November (107)
    • October (151)
    • September (120)
    • August (110)
    • July (123)
    • June (109)
    • May (117)
    • April (129)
    • March (153)
    • February (130)
    • January (129)
  • 2013 (1601)
    • December (125)
    • November (176)
    • October (172)
    • September (162)
    • August (131)
    • July (140)
    • June (114)
    • May (123)
    • April (146)
    • March (123)
    • February (87)
    • January (102)
  • 2012 (781)
    • December (23)
    • November (18)
    • October (24)
    • September (78)
    • August (90)
    • July (67)
    • June (68)
    • May (97)
    • April (88)
    • March (86)
    • February (77)
    • January (65)
  • 2011 (449)
    • December (59)
    • November (73)
    • October (23)
    • September (31)
    • August (44)
    • July (34)
    • June (14)
    • May (43)
    • April (20)
    • March (42)
    • February (29)
    • January (37)
  • 2010 (356)
    • December (32)
    • November (45)
    • October (45)
    • September (51)
    • August (58)
    • July (43)
    • May (6)
    • April (1)
    • March (35)
    • February (17)
    • January (23)
  • 2009 (252)
    • December (20)
    • November (18)
    • October (22)
    • September (20)
    • August (15)
    • July (19)
    • June (20)
    • May (20)
    • April (19)
    • March (22)
    • February (19)
    • January (38)
  • 2008 (420)
    • December (38)
    • November (36)
    • October (46)
    • September (40)
    • August (34)
    • July (38)
    • June (36)
    • May (42)
    • April (42)
    • March (28)
    • February (40)

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2021. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
December 29, 2020 December 29, 2020
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Accept settingsHide notification only